{"id":961279,"date":"2026-05-12T07:22:03","date_gmt":"2026-05-12T11:22:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"},"modified":"2026-05-12T07:22:03","modified_gmt":"2026-05-12T11:22:03","slug":"cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","title":{"rendered":"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">FREDERICK, Md., May  12, 2026  (GLOBE NEWSWIRE) &#8212; Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the \u201cCompany\u201d), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4<sup>th<\/sup> Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET.<\/p>\n<p align=\"justify\">A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company\u2019s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.<\/p>\n<p align=\"justify\">\n        <strong>About Cartesian Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company\u2019s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1\/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dAHuNm1qqEegRaUcarMRBaGcerqcOoo2Z4CHgaLujUE9eOTnemoCH5CVJVuNBpAr51RAAroI0o2OUvM79L4Grvhw1Oo0vYTYyyX7SFig09ogvCba7o2WUPfgw4M4zhc3\" rel=\"nofollow\" target=\"_blank\">www.cartesiantherapeutics.com<\/a> or follow the Company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0WfxsgQjlgFDU0AJztSlXKNK4ZPL3tIKlYVZ_fJcA-PRGx9uuh2l1MG82A1KqMvfdmE6ghBZOARVRVH3F6Nh3bu8JsB3NNjzMMTZy5iZXDZ4GPaJWHAMrm7zqRd4LnaC\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5GdXKcCQLnq45xL9jh7CHaYzdfw0_DtCifze5rkOHhpCYL4UEvQF8CSCXx2NVIhM-JRp1R_pBBxcdFSP5DseFA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Megan LeDuc<br \/>Associate Director, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DmvMY--RCGM-uaSKGVvVAy3odfQUNaQszLkedLkinjJnGeJlLoQQObMd7VgqE5vBfO5fMpEBHXbWEIS0h66Ep2g5ovgqzRL2gvXWPTzB9lnTJLWi5Rej2i--9fo9Te5B\" rel=\"nofollow\" target=\"_blank\">megan.leduc@cartesiantx.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p align=\"justify\">David Rosen<br \/>Argot Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nw1trIIWNXkl86BI83byoLg4jiNrp7lkVm7CWe5-p6AcQZ0fk1x9otOFmCtYz0Y90Ax8GxxFWjHhwddeeTSg-tm2R_kI7W2txc-v5mEYpE4ZHRIFQZ_JSQa0T74w_X5W\" rel=\"nofollow\" target=\"_blank\">david.rosen@argotpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzM3YTBhZDktMDllMy00OTA2LWE5NTItNGY1OWFiZmQxYTRhLTEwNjE3MDAtMjAyNi0wNS0xMi1lbg==\/tiny\/Cartesian-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) &#8212; Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the \u201cCompany\u201d), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company\u2019s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company\u2019s lead asset, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-961279","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) &#8212; Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the \u201cCompany\u201d), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company\u2019s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company\u2019s lead asset, &hellip; Continue reading &quot;Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T11:22:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\",\"datePublished\":\"2026-05-12T11:22:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\"},\"wordCount\":209,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\",\"name\":\"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=\",\"datePublished\":\"2026-05-12T11:22:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","og_locale":"en_US","og_type":"article","og_title":"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk","og_description":"FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) &#8212; Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the \u201cCompany\u201d), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company\u2019s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company\u2019s lead asset, &hellip; Continue reading \"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-12T11:22:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ","datePublished":"2026-05-12T11:22:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"},"wordCount":209,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","name":"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=","datePublished":"2026-05-12T11:22:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzg0NyM3NTk1NjI4IzIwNTAxMjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=961279"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961279\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=961279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=961279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=961279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}